Risk of stage underestimation of breast cancer by sentinel lymph node biopsy method;Du risque de sous-traitement des cancers du sein en utilisant la technique du ganglion sentinelle

Bulletin du Cancer

Volumn 90, Issue 5, 2003, Pages 467-473

  Houvenaeghel, Gilles ^a   Martino, Marc ^a   Jacquemier, Jocelyne ^a   Moutardier, Vincent ^a   Tallet, Agnès ^a   Viens, Patrice ^a   Puig, Brigitte ^a   Bardou, Valérie Jeanne ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Breast; Cancer; Lymph node metastasis; Sentinel lymph node

Indexed keywords

HORMONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; AGE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIVARIATE ANALYSIS; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PATHOLOGY; PATIENT CARE PLANNING; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY; STANDARD;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM STAGING; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 0043208101     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival. J Am Coll Surg 1999; 188: 586-95.
2. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomised clinical trial comparing radical mastectomy and total masrectomy with or without radiation. N Engl J Med 1985; 312: 674-81.
3. Ververs JM, Roumen RM, Vingerhoets A J, Vreugdenhil G, Coebergh JW, Crommelin MA, et al. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 2001; 37: 991-9.
4. Kakuda JT, Stuntz M, Trivedi V, Klein SR, Vargas HI. Objective assessment of axillary morbidity in breast cancer treatment. Am Surg 1999; 65: 995-8.
5. Ganz PA. The quality of life after breast cancer-solving the problem of lymphedema. N Engl J Med 1999; 340: 383-5.
6. Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwarer G, Peterson B, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998; 83: 1362-8.
7. White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg 1996; 183: 575-82.
8. Cabanes PA, Salmon RJ, Vilcoq JR, Durand JC, Fourquer A, Gautier C, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Laner 1992; 339: 1245-8.
9. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian mera-analysis. Ann Surg Oncol 1999; 6: 109-16.
10. Danforth DN, Findlay PA, McDonald HD, Lippman ME, Reichert CM, d'Angelo T, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986; 4: 655-62.
11. Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987; 59: 682-7.
12. Boova RS, Bonanni R, Rosato FE. Patterns of axillary nodal involvement in breast cancer: predictability of-level one dissection. Ann Surg 1982; 196: 642-4.
13. Chevinsky AH, Ferrara J, James AG, Minton JP, Young D, Farrar WB. Prospective evaluation of clinical and pathologic derection of axillary metastases in patients with carcinoma of the breast 1990; 108: 612-7.
14. Gaglia P, Bussone R, Caldarola B, Lai M, Jayme A, Caldarola L. The correlation between the spread of metastases by level in the axillary nodes and disease-free survival in breast cancer: a multifactorial analysis. Eur J Cancer Clin Oncol 1987; 23: 849-54.
15. Van Lancker M, Goor C, Sacre R, Lamote J, Van Belle S, De Coene N, et al. Patterns of axillary lymph node metastasis in breast cancer. Am J Clin Oncol 1995; 18: 267-72.
16. Roses DF, Brooks AD, Harris MN, Shapiro RL, Mirnick J. Complications of level I and II axillary dissection in the treatment of carcinoma of rhe breast. Ann Surg 1999; 230: 194-201.
17. Giuliano AE. Mapping a pathway for axillary sraging: a personal perspective on the current status of sentinel lymph node dissection for breast cancer. Arch Surg 1999; 134: 195-9.
18. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a dererminant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981; 152: 765-72.
19. Sacre RA. Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol 1986; 12: 169-73.
20. Noguchi M, Ohra N, Thomas M, Kitagawa H, Earashi M, Miyazaki I, et al. Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer. Surg Oncol 1993; 2: 51-8.
21. Davies GC, Millis RR, Hayward JL. Assessment of axillary lymph node status. Ann Surg 1980; 192: 148-51.
22. Voogd AC, Coebergh JW, Repelaer vDO, Roumen RM, van Beek MW, Vreugdenhil A, et al. The risk of nodal metastases in breast cancer parients with clinically negative lymph nodes: a population-based analysis. Breast Caner Res Treat 2000; 62: 63-9.
23. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88: 608-14.
24. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissecrion for breast cancer. Am J Surg 2002; 183: 23-7.
25. Carrer CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
26. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1,446 cases of breast cancer. Eur J Surg Oncol 1990; 16: 127-33.
27. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999; 230: 692-6.
28. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997; 79: 1918-22.
29. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patienrs with T1 breast cancer: a multivariate analysis. Cancer 1994; 73: 350-3.
30. Olivotto IA, Jackson JS, Mates D, Andersen S, Davidson W, Bryce CJ, Ragaz J. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 1998; 83: 948-55.
31. Fein DA, Fowble BL, Hanlon AL, Hooks MA, Hoffman JP, Sigurdson ER, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997; 65: 34-9.
32. Port ER, Tan LK, Borgen PI, Van Zee KJ. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Ann Surg 1998; 5: 23-7.
33. Clemente CG, Boracchi P, Andreola S, Del Vecchio M, Veronesi P, Rilke FO. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992; 69: 1396-403.
34. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76: 1772-8.
35. Fischer ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metasrases in patients with invasive breast cancer. Cancer 1978; 42: 2025-31.
36. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990; 335: 1565-68.
37. Hsueh EC, Turner RR, Glass EC, Brenner RJ, Brennan MB, Giuliano AE. Senrinel node biopsy in breast cancer. J Am Coll Surg 1999; 189: 207-13.
38. Giuliano AE, Barth AM, Spivack B, Beirsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996; 183: 185-9.
39. Gann PH, Colilla SA, Gapsur SM, Winchester DJ, Winchester DE Factors associated with axillary lymph node metastasis from breast carcinoma: descriptive and predictive analyses. Cancer 1999; 86: 1511-9.
40. Ravdin PM, De Laurentiis M, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of pronostic indicators. J Natl Cancer Inst 1994; 86: 1771-5.
41. Shetty MR. Axillary lymph node metastasis in carcinoma ofrhe breast. J Am Coll Surg 1997; 184: 671-3.
42. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne ME. Predicrive factors associated with axillary lumph node metastases in T1a et T1b breast carcinomas: analysis in more than 900 parients. J Am Coll Surg 2000; 191: 1-6.
43. Schwartz GF, Patchefsky AS, Finklestein SD, Sohn SH, Prestipino A, Feig SA, et al. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentticity and microinvasion and implications for treatment. Arch Surg 1989; 124: 29-32.
44. Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, et al. Microinvasive ducral carcinoma of the breast treated-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23: 961-8.
45. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated ? Cancer 1994; 73: 664-7.
46. McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982; 6: 401-11.
47. McMastets KM, Wong SL, Chao C, Woo C, Tuttle TM, Noyes RD, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph biopsy: a model for implementation of new surgical techniques. Ann Surg 2001; 234: 292-9 {discussion : 299-300}.
48. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients ith sentinel node-negative breast cancer. J Clin Oncol 2000; 18: 2553-9.
49. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Crasne DL. Improved axillary staging of breast cancer with sentinel lymphadenecromy. Ann Surg 1995; 222: 394-9 {discussion : 399-401}.
50. Dowlarshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80: 1188-97.
51. Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC. Occult metastases in sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer 1999; 86: 990-6.
52. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer 1995; 55: 3417-20.
53. Wells CA, Heryer A, Brochier J, Garter KC, Mason DY. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984; 50: 193-7.
54. Friedman S, Bertin F, Mouriese H, Benchabat A, Genin J, Sarrazin D, Contesso G. Importance of tumor cells in axillary node sinus margins (« clandestine » metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol 1988; 27: 483-7.
55. Fischer ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cnacer. Cancer 1978; 42: 2025-31.
56. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981; 194: 585-91.
57. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994; 73: 505-8.
58. Trojani M, de M, I, Coindre JM, Bonichon F. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 56: 838-9.
59. Hainswortb PJ, Tjandra JJ, Stillwell RG, Machet D, Henderson MA, Rennie GC, McKenzie IF, Bennett RC. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80: 459-63.
60. Neville AM, Price KN, Gelber RD, Goldhirsch A. Axillary node micrometastases and breast cancer. Lancet 1991; 337: 1110.
61. De Mascarel, I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66: 523-7.
62. Chen ZL, Wen DR, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and hisrologic examination and conventional histology. Dis Markers 1991; 9: 239-48.
63. Loprinzi CL, Thome SD. Undetsranding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001; 19: 972-9.
64. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42.
65. Vetonesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91: 368-73.
66. Graversen HP, Blicherr-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node negarive parients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14: 407-12.
67. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992; 28A: 1415-8.
68. Wilking N, Rurqvist LE, Carstensen J, Lattsson A, Skoog L. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm Breast Cancer Study Group. Acta Oncol 1992; 31: 29-35.
69. Fisher B., Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten year results of a randomised clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674-81.
70. Mignotte H, Treilleux I, Chassagne-Clément C, Bern C, Lopez R, Martin X, et al. Intérêt de l'injecrion péri-aréolaire du colorant lymphotrope dans la recherche du ganglion axillaire sentinelle dans le cancer du sein. Bull Cancer 2000; 87: 600-3.
71. e édition, mise à jour, version abrégée. Bull Cancer 2002; 89: 207-24.
72. Sounding board: sentinel-lymph-node biopsy for breast cancer: not yet the standard of care. N Engl J Med 1998; 339: 990-5.
73. Hill AD, Tran KN, Akhurst T, Yeung H, Yeh SD, Rosen PP, Borgen PI, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999; 229: 528-35.
74. Pendas S, Dauway E, Cox CE, Giuliano R, Ku NN, Schreiber RH, Reintgen DS. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999; 65: 500-5.
75. Moutardier V, Houvenaeghel G. Biopsie du ganglion sencinelle dans le cancer du sein: courbe d'apprentissage er contrôle qualité Bull Cancer 2001; 88: 1246-7.
76. Rodier JF. Le repérage du ganglion sentinelle par le chirurgien. Bull Cancer 2002; 89: 840-4.